MedTrace Logo

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

NCT03892421 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-05-18

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy and safety of a combination of the anti-CD20 monoclonal antibody Rituximab, Dexamethasone, daily high dose Cytarabine twice, and Carboplatin; delivered in an outpatient setting.

Conditions

  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma

Interventions

DRUG

Rituximab

Rituximab 375 mg/m²

DRUG

Carboplatin

Carboplatin AUC5

DRUG

Cytarabine Injection

Cytarabine 2000 mg/m² qd 2 days

DRUG

Dexamethasone

Dexamethasone 40 mg

DRUG

Filgrastim 0.3 MG/ML

One subcutaneous injection daily for 5 days

Sponsors & Collaborators

  • La Raza Medical Center

    lead OTHER

Principal Investigators

  • Study Officials H Caballero, MD Ms · Hematology Department La Raza Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-05
Primary Completion
2021-01-30
Completion
2021-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892421 on ClinicalTrials.gov